In this week's Homerun Slides, the effectiveness of Lixisenatide when added to basal insulin, and strategies for avoiding or minimizing the GI effects of GLP-1.

Each week we try to bring you the latest in diabetes care, and some of you often email me about the Homerun Slides and how they often explore therapies with drugs that are not available to use in practice. This week’s Slides look at studies using a yet-to-be-approved GLP-1 analog …

One of your patients has referred her 21-year-old stepson for a new patient exam. He has recently arrived home from college for the summer and she is concerned because he always seems to be thirsty. When prompted, she recalls her husband saying his ex-wife struggled with her weight and took “pills for her blood sugar.” Physical examination is notable for mildly elevated BP (137/84) and BMI 26 kg/m2. He denies any cigarette or alcohol use, states his favorite activities revolve around video games, and that he doesn’t really enjoy any physical activities. Labs are notable for random plasma glucose 312 mg/dl, UA positive for glucose. What would your initial drug therapy strategy be? Follow the link to take the quiz!

There has been a lot of press concerning the use of SGLT-2 Inhibitors and the possibility of DKA. Logically speaking it would seem that anything that lowers glucose would be of benefit in preventing DKA, but for some reason the human body seems to defy logic. With this in mind …

Will the current information for SGLT-2 inhibitors prevent you from recommending it for diabetes treatment? Follow the link to take the poll!

Diabetes experts conclude diabetes treatment should continue with no changes in current recommendations.

Depressive symptoms are more common than diagnoses and treatment.

The FDA is requiring the drug company to submit more clinical data.

Blood group also possible indicator of development of gestational diabetes itself.

Patient history of CVD, higher A1C factored into risk.